Shenapharm Limited - Accounts to registrar (filleted)

REGISTERED NUMBER: 11784404 (England and Wales)

Financial Statements for the Year Ended 31 January 2025

for

Shenapharm Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTOR:

Mrs S A Fiaz

SECRETARY:

REGISTERED OFFICE:

39 Gerrard Avenue

Rochester

Kent

ME1 2RW

REGISTERED NUMBER:

11784404 (England and Wales)

ACCOUNTANTS:

MSR GROUP LTD

MSR House

329 Ley Street

Ilford

Essex

IG1 4AA

FIXED ASSETS

Tangible assets

4

3,260

3,600

CURRENT ASSETS

Debtors

5

20,825

13,905

Cash at bank

6,510

9,401

27,335

23,306

CREDITORS

Amounts falling due within one year

6

10,680

10,423

NET CURRENT ASSETS

16,655

12,883

TOTAL ASSETS LESS CURRENT
LIABILITIES

19,915

16,483

CAPITAL AND RESERVES

Called up share capital

100

Retained earnings

19,815

16,383

SHAREHOLDERS' FUNDS

19,915

16,483

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 5 September 2025 and were signed by:

Mrs S A Fiaz - Director

1.	STATUTORY INFORMATION

Shenapharm Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2024 - 1 ).

4.	TANGIBLE FIXED ASSETS

Plant and

machinery

etc

£

COST

At 1 February 2024

and 31 January 2025

4,000

DEPRECIATION

At 1 February 2024

400

Charge for year

340

At 31 January 2025

740

NET BOOK VALUE

At 31 January 2025

3,260

At 31 January 2024

3,600

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.1.25

31.1.24

£

Other debtors